CDKN2A/B缺失与局灶性基因扩增可细化IDH1/2突变型星形细胞瘤的预后分层
研究纳入1989至2020年间998例IDH1/2突变型星形细胞瘤患者,分析组织学分级、CDKN2A/B状态与局灶性基因扩增对生存的影响。结果显示组织学2/3级且CDKN2A/B完整、无局灶扩增者生存最长,而伴CDKN2A/B半合子缺失或局灶扩增者生存与4级且CDKN2A/B完整无扩增者无显著差异。整合CDKN2A/B状态与扩增信息可细化IDH突变型星形细胞瘤的预后分层。
要点
- 组织学2/3级且CDKN2A/B完整无扩增者生存最长,中位OS 205.7个月。
- 2/3级伴CDKN2A/B半合子缺失或局灶扩增者OS分别为80.4和88.7个月,与4级完整无扩增者91.5个月无显著差异(P=.93)。
- 4级伴CDKN2A/B半合子或纯合缺失者OS最短,分别为31.9和32.5个月。
核心结论
- 联合CDKN2A/B半合子缺失与局灶性基因扩增可识别出一组预后居中的IDH1/2突变型星形细胞瘤患者,从而细化该类肿瘤的分类。
研究设计与样本
- 研究纳入1989至2020年间来自公共数据集及多家学术医学中心的998例≥19岁IDH1/2突变型星形细胞瘤患者(女性41.5%,白人85.6%),采用多因素建模与无偏聚类进行风险分层。
主要发现
- 肿瘤分级、CDKN2A/B缺失和/或≥1个局灶性扩增与生存期缩短相关。
- 组织学2/3级且CDKN2A/B完整、无局灶扩增者生存最长,OS 205.7个月。
- 2/3级伴CDKN2A/B半合子缺失者OS 80.4个月、伴局灶扩增者OS 88.7个月,与4级且CDKN2A/B完整无扩增者OS 91.5个月相比无显著差异(P=.93)。
- 4级伴CDKN2A/B半合子缺失者OS 31.9个月、伴纯合缺失者OS 32.5个月,为最短;4级且CDKN2A/B完整伴局灶基因扩增者OS 55.9个月。
- 无偏聚类识别出9种不同分子图谱,生存期存在差异;任何CDKN2A/B缺失的IDH1/2突变型星形细胞瘤无论分级均聚类在一起,预后最差。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Molecular features have been incorporated alongside histologic criteria to improve glioma diagnostics and prognostication. CDKN2A/B homozygous-loss associates with worse survival in IDH1/2-mutant astrocytomas (IDHmut-astrocytomas), the presence of which denotes a grade 4 tumor independent of histologic features. However, no molecular features distinguish survival amongst histologically defined grade 2 and 3 IDHmut-astrocytomas. METHODS: We assembled a cohort of patients ≥19 years old diagnosed with an IDHmut-astrocytoma between 1989 and 2020 from public datasets and several academic medical centers. Multivariate modeling and unbiased clustering were used to stratify risk. RESULTS: We identified 998 IDHmut-astrocytoma patients (41.5% female; 85.6% white). Tumor grade, CDKN2A/B loss, and/or ≥1 focal amplification were associated with reduced survival. Grade 2/3 patients with intact CDKN2A/B and no focal amplifications survived the longest (OS 205.7 months). Survival for grade 2/3 cases with either CDKN2A/B hemizygous-loss or focal amplifications (80.4, 88.7 months respectively) did not differ significantly from grade 4 cases with intact CDKN2A/B and no amplifications (91.5 months, P = .93). Grade 4 patients with either hemizygous or homozygous loss of CDKN2A/B had the shortest survival (OS 31.9, 32.5 months respectively), followed by grade 4 cases with intact CDKN2A/B and focal gene amplifications (OS 55.9 months). Integrating CDKN2A/B status and amplifications alongside histopathologic grade refined overall survival prediction. Unbiased clustering revealed 9 distinct molecular profiles, with differential survival. IDHmut-astrocytomas with any CDKN2A/B loss clustered together, regardless of grade, and exhibited the poorest outcomes. CONCLUSIONS: Combining CDKN2A/B hemizygous-loss and focal gene amplifications reveals a group of IDHmut-astrocytoma patients with an intermediate prognosis, refining IDHmut-astrocytoma classification.
引用
- Ghosh HS, Patel RV, Claus EB, et al. Canonical amplifications and CDKN2A/B loss refine IDH1/2-mutant astrocytoma prognosis. Neuro Oncol. 2025. PMID: 39584448. doi:10.1093/neuonc/noae258
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。